Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
Status:
Recruiting
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab
deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are
ctDNA positive after chemotherapy and surgery. 25 patients will be recruited from
approximately 15 NHS secondary care sites.